{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"2.7","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.\n\nToxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.\n\nSchedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.\n\nSchedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.\n\nSchedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.\n\nSchedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.","id":"OG000","title":"Melphalan and Panobinostat"}],"paramType":"MEDIAN","populationDescription":"All cohorts were analyzed","reportingStatus":"POSTED","timeFrame":"Time from the start of treatment to progressive disease","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"months"}